Dani Castillo, Medical Oncologist and Researcher in COH, shared Nieves Martinez Lago’s, Specialist in the Field (FEA) of Medical Oncology at University Hospital Complex of Santiago de Compostela, post on X, adding:
“Periscope II should not be interpreted as evidence that regional therapy has no role in GCPM.
It demostrates CRS+ HIPEC did not improve OS without biomarker guided systemic tx alone in unselected population with PCI < 7, diff from piano study, next step should focus on IO and Taget tx ( more effective systemic tx) and translational endpoints that should will benefit.”
Quoting Nieves Martinez Lago’s post:
“PERISCOPE II | Phase III
Gastrectomy + CRS/HIPEC vs ChT alone for limited peritoneal mGC
No OS benefit: 15.7 vs 16.6 months (HR 1.10)
- + grade ≥3 AEs: 42% vs 20%
- TR deaths: 3 vs 0
do not support routine CRS/HIPEC in this setting”
Title: Systemic therapy, gastrectomy, cytoreductive surgery, and hyperthermic intraperitoneal chemotherapy versus systemic therapy alone for gastric cancer with limited peritoneal metastases (PERISCOPE II): final results of a multicentre, randomised, controlled, phase 3 trial after an unplanned commissioned interim analysis
Authors: Judith S E Quik, Marieke A Vollebergh, Valesca P Retèl, Karen van der Sluis, Willem J Koemans, Rosa T van der Kaaij, Madelon M Voets, Misha D P Luyer, Irene E G van Hellemond, Bas P L Wijnhoven, Bianca Mostert, Richard van Hillegersberg, Nadia Haj Mohammad, Boudewijn van Etten, Derk J de Groot, Olli Helminen, Jakob Hedberg, Peter H Cashin, Julie L Harbjerg, Alexander A F A Veenhof, Koen J Hartemink, Liudmila L Kodach, Vincent van der Noort, Johanna W van Sandick.
Other articles about Periscope II on OncoDaily.